You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Diffuse large B-cell lymphoma

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)

Active, not recruiting
Has Results
  • Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
  • Los Angeles, California
  • +6 more
Dec 1, 2022

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
Dec 1, 2022

Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma

Completed
  • Lymphoma, Large B-cell, Diffuse
    • Jeonju, Korea, Republic of
      Chonbuk National University Hospital
    Feb 2, 2023

    DLBCL - Diffuse Large B Cell Lymphoma Trial in Toronto (Cyclophosphamide, TLI)

    Recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Jul 19, 2023

    Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Dec 12, 2022

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Diffuse Large B Cell Lymphoma
    • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Nov 19, 2023

    The First Affiliated Hospital of Nanchang University Trial in Nanchang, Jinan (Orelabrutinib+R-CHOP)

    Recruiting
    • The First Affiliated Hospital of Nanchang University
    • Nanchang, Jiangxi, China
    • +1 more
    Jul 3, 2023

    Diffuse Large B Cell Lymphoma Trial in Wuhan (Zanubrutinib plus RCHOP)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Zanubrutinib plus RCHOP
    • Wuhan, Hubei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Aug 16, 2023

    Diffuse Large B Cell Lymphoma Trial (Venetoclax, Carmustine, Cytarabine)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    May 9, 2023

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

    Withdrawn
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +9 more
    • Autologous Hematopoietic Stem Cell Transplantation
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 11, 2023

    Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

    Not yet recruiting
    • Recurrent ALK Positive Large B-Cell Lymphoma
    • +28 more
    • Biospecimen Collection
    • +5 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Aug 17, 2022

    Tisagenlecleucel in Brazilian Acute Lymphoblastic Leukemia or

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • Acute Lymphoblastic Leukemia
    • tisagenlecleucel
    • (no location specified)
    Sep 13, 2022

    Communication Training Intervention for Large B-Cell Lymphoma

    Recruiting
    • Lymphoma, B-Cell
    • +5 more
    • Hematolo-GIST Training
    • Participants Appointment
    • New York, New York
    • +2 more
    Jul 3, 2023

    Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

    Not yet recruiting
    • Follicular Lymphoma
    • +3 more
    • Tazemetostat Pill
    • New York, New York
      Weill Cornell Medicine/NewYork-Presbyterian Hospital
    Jun 28, 2023

    Tafasitamab in Combination With Lenalidomide in Patients withR/R

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • Tafasitamab Injection
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    May 31, 2023

    Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)

    Recruiting
    • Relapsed Diffuse Large B-cell Lymphoma
    • loncastuximab tesirine
    • Detroit, Michigan
      Barbara Ann Karmanos Cancer Institute
    Jun 24, 2022

    Diffuse Large B-cell Lymphoma Trial in Hangzhou, Ningbo (CD19-7×19 CAR-T combined with Tislelizumab)

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • CD19-7×19 CAR-T combined with Tislelizumab
    • Hangzhou, Zhejiang, China
    • +1 more
    Dec 12, 2022

    Diffuse Large B-cell-lymphoma Trial in Saint Louis, Cleveland (Venetoclax, Rituximab, Ifosfamide)

    Active, not recruiting
    • Diffuse Large B-cell-lymphoma
    • Saint Louis, Missouri
    • +2 more
    Nov 14, 2022

    Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy Trial (ultra-fraction radiotherapy)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • ultra-fraction radiotherapy
    • (no location specified)
    Aug 22, 2022

    Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma

    Completed
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • CAR-T
    • Allo-HSCT cohort
    • East Hanover, New Jersey
      Novartis Investigative Site
    Jun 29, 2022

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 30, 2022

    B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • +2 more
    • CD19/CD22-bispecific CAR-T cells
    • Beijing, Beijing, China
      Liang Wang
    Oct 7, 2023

    Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Sep 18, 2023

    Diffuse Large B-cell Lymphoma Trial in Chapel Hill (Polatuzumab vedotin (PV), Rituximab, Hyaluronidase)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • Polatuzumab vedotin (PV)
    • +6 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center
    Aug 9, 2022